Achillion to Present at the Baird 2018 Global Healthcare Conference
August 30, 2018 06:00 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will...
Achillion Appoints Dr. Steven Zelenkofske as Chief Medical Officer and Further Strengthens Clinical Development Team
August 21, 2018 06:00 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Steven Zelenkofske, D.O. to the position of Executive Vice...
Achillion Expands Management Team With Appointment of Anthony S. Gibney as Chief Business Officer
August 15, 2018 16:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced the appointment of Anthony S. Gibney to the position of Executive Vice President...
Achillion Reports Second Quarter 2018 Financial Results
August 08, 2018 16:05 ET
|
Achillion Pharmaceuticals, Inc.
- Global phase 2 clinical programs for ACH-4471 continue to expand in PNH and C3G -- Completed dosing phase 1 clinical study of ACH-5228 and initiated phase 1 study of ACH-5548 -- June 30, 2018 cash...
Achillion Initiates Phase I First-in-Human Study of ACH-5548, a Third Oral Small Molecule Inhibitor of Complement Factor D
July 10, 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
- Additional clinical compounds expand factor D portfolio opportunities - NEW HAVEN, Conn., July 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a clinical-stage...
Achillion to Present at the 2018 JMP Securities Life Sciences Conference
June 14, 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., June 14, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present...
Achillion Announces Upcoming Scientific Presentations at the 55th ERA-EDTA Congress
May 11, 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
- Oral presentation discussing ACH-4471 and interim biomarker data from the ongoing 14-day Phase 2 study in C3G - - Poster presentation detailing in vitro data showing no significant reduction in...
Achillion to Present at the Deutsche Bank 43rd Annual Health Care Conference
May 04, 2018 06:35 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., May 04, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present...
Achillion Reports First Quarter 2018 Financial Results and Management Transition
May 02, 2018 06:35 ET
|
Achillion Pharmaceuticals, Inc.
- Plans for clinical data in C3 glomerulopathy (C3G) and for paroxysmal nocturnal hemoglobinuria (PNH) remain on track for 2018 - - Joseph Truitt appointed Chief Executive Officer - NEW HAVEN,...
Achillion to Present at the Barclays Global Healthcare Conference
March 08, 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., Chief Executive Officer of Achillion, will present a...